Stay up-to-date with the Cipla Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on a ...

Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, ...

Cipla faces headwinds but remains resilient with strong product portfolio, robust earnings growth potential, and reasonable ...

With Eli Lilly’s Mounjaro entering India, the weight-loss drug race is on. But with steep prices and generics on the way, how ...

Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 ...

Jio Financial Services, IOB, NBCC, Indian Oil, IRFC, Exide Industries, Cipla and ACC shares top stocks to buy recommendation ...

Obesity affects approximately 100 million Indian adults and is linked to over 200 health complications, including heart ...

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain ...

Cipla has announced an exclusive licensing agreement ... across 11 countries, including India. It is used to treat post-op inflammation and pain following ocular surgery.